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ABSTRACT
Two anti-epidermal growth factor receptor (EGFR) 
monoclonal antibodies (MoAbs) have been approved 
in Canada for the treatment of metastatic colorectal 
cancer (mCRC) – cetuximab, a mouse-human chime-
ric MoAb, and panitumumab, a fully human MoAb.   
This paper reviews the efficacy of the anti-EGFR 
monoclonal antibodies cetuximab and panitumumab 
– both as monotherapy and in combination with cy-
totoxic chemotherapy – in the treatment of mCRC. 
Both cetuximab and panitumumab have demonstrated 
clinical efficacy in monotherapy in patients with 
mCRC, an advantage that has recently been found 
to be limited largely to those with wild-type KRAS 
tumors. Advantages of using these agents in mono-
therapy include reduced cost and toxicity. While the 
addition of cetuximab to irinotecan has shown supe-
rior progression-free survival and response compared 
with cetuximab monotherapy, there is currently no 
evidence for a benefit of panitumumab in combina-
tion with irinotecan.
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1.  InTRODuCTIOn
There are an estimated 22,000 new cases of colorec-
tal cancer (CRC) each year in Canada. CRC is the 
second leading cause of death from cancer after lung 
cancer, accounting for more than 9,000 deaths each 
year1. When diagnosed in the early stages of disease, 
CRC is associated with a five-year survival rate of 
up to 90%2. However, for those with metastatic CRC 
(mCRC), which represents approximately 20% of first 
diagnoses, the five-year survival rate is only 10%2,3. 
With the introduction of treatments involving irino-
tecan or oxaliplatin in combination with fluorouracil 
and leucovorin, survival has improved for patients 
with mCRC over the past decade4-17. However, as 
most patients eventually develop resistance to these 
therapies, new active treatment options in this setting 
were needed.
Insights into the molecular pathogenesis of CRC 
prompted the development of specific target-directed 
therapies for the treatment of mCRC, including mono-
clonal antibodies (MoAbs) that target the epidermal 
growth factor receptor (EGFR). The two anti-EGFR 
MoAbs approved in Canada for the treatment of 
mCRC are cetuximab, a mouse-human chimeric 
MoAb, and panitumumab, a fully human MoAb. 
2.  RATIOnAlE fOR ThE uSE Of AnTI-EGfR 
MOABS In ThE TREATMEnT Of MCRC
EGFR – also known as HER-1 or erb-B1 – is a ubiq-
uitous transmembrane glycoprotein that contains an 
amino-terminal extracellular ligand-binding domain, 
a hydrophobic transmembranous region, and a cyto-
plasmic domain. Within the cytoplasmic domain there 
is a tyrosine kinase domain and a carboxy-terminal 
region, which contains critical tyrosine residues and 
receptor regulatory motifs18.
EGFR is abnormally activated in a number of 
human malignancies, through several mechanisms, 
including receptor overexpression, gene ampli-
fication, activating mutations, overexpression of 
receptor ligands, and/or loss of negative regulatory 
mechanisms19. EGFR activation of the receptor 
leads to recruitment and phosphorylation of several 
intracellular substrates which, in turn, engage tumor-
promoting activities19. 
Elevated EGFR expression has been documented 
in 60% to 80% of patients with mCRC20,21, and cor-
relates with disease progression, metastatic spread, 
and poorer prognosis22. Pharmacologic interventions 
have therefore been developed to target the molecular 
and cellular consequences of EGFR alterations23,24. 
One such intervention has been the use of MoAbs that 
compete with the binding of activating ligands to the 
extracellular domain of the receptor.
Two MoAbs that bind and block EGFR signaling 
are currently approved in Canada for the treatment 
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of mCRC. The first drug approved in this class was 
cetuximab (ErbituxTM; Bristol-Myers Squibb/Im-
Clone Systems Incorporated, Montreal, Quebec), 
an immunoglobulin (Ig) G1 human-mouse chimeric 
MoAb. Cetuximab is approved both as a monotherapy 
and in combination with irinotecan for the treatment 
of mCRC that is refractory to other irinotecan-based 
chemotherapy regimens25. Panitumumab (VectibixTM, 
Amgen, Mississauga, Ontario) is an IgG2 fully hu-
man MoAb directed against the EGFR, and has been 
approved for use as monotherapy for the treatment 
of EGFR-expressing mCRC with wild-type KRAS 
after failure of fluoropyrimidine-, oxaliplatin-, and 
irinotecan-containing chemotherapy regimens26. 
Cetuximab and panitumumab bind to the easily ac-
cessible extracellular domain of the receptor and com-
pete with ligand binding. This blocks the downstream 
signaling of EGFR, resulting in impaired cell growth 
and proliferation25-28. In addition, cetuximab has been 
suggested to induce antibody-mediated cellular cyto-
toxicity (ADCC) due to its human IgG1 backbone, 
which may contribute to its anti-tumor effects29,30.
3.  EffICACY Of ThE AnTI-EGRf MOABS
3.1  Cetuximab
3.1.1  Cetuximab monotherapy
A series of phase II and phase III trials have evalu-
ated the efficacy of cetuximab monotherapy in the 
treatment of patients with mCRC who failed to re-
spond to previous treatment with irinotecan31-34. In 
the first phase II open-label trial31, 57 patients with 
EGFR-expressing mCRC who had been unresponsive 
to previous treatment with irinotecan were given 
cetuximab by weekly intravenous infusion at the 
standard dosage – 400 mg/m2 over 2 hours in the first 
dose, followed by subsequent weekly treatments of 
250 mg/m2 over 1 hour. Sixteen patients (28%) had 
received one prior regimen for their disease before 
study entry. Forty-one patients (72%) had received 
two or more chemotherapy regimens (including adju-
vant regimens, if given) for their disease before study 
entry. A partial response was observed in six patients 
(10.5%; 95% CI 4–22%). Twenty additional patients 
experienced a minor response, defined as a tumor 
reduction of 25% to 49%, or stable disease, defined 
as either growth or shrinkage of less than 25% lasting 
for a minimum of 12 weeks from the start of treat-
ment. The median time to tumor progression was 1.4 
months, with a median survival of 6.4 months from 
the initiation of cetuximab. 
Among 346 patients with EGFR-expressing 
mCRC refractory to irinotecan, oxaliplatin, and 
fluoropyrimidines, cetuximab given at the standard 
dosage elicited a response rate of 12.4% (95% CI 
9.1–16.4%)32. Median progression-free survival 
(PFS) and overall survival (OS) times were 1.4 
months (95% CI 1.4–2.1 months) and 6.6 months 
(95% CI 5.6–7.6 months), respectively. Patients 
enrolled in this study had received a median of four 
prior chemotherapy regimens (range 2 to 9). All 
patients had been treated with both irinotecan- and 
oxaliplatin-based regimens, with 93.6% and 98.3% 
developing progressive disease during treatment or 
within three months of treatment with these agents, 
respectively, in the metastatic setting.
In comparison with best supportive care (BSC), 
cetuximab has demonstrated significant improve-
ments in survival in patients with mCRC. In the phase 
III CO.17 trial conducted by the National Cancer 
Institute of Canada Clinical Trials Group (NCIC 
CTG) and the Australasian Gastro-Intestinal Trials 
Group (AGITG), Jonker et al. randomly assigned 
572 patients with EGFR-expressing mCRC refrac-
tory to fluoropyrimidine, irinotecan, and oxaliplatin 
to standard-dose cetuximab plus BSC (n = 287) or 
BSC alone (n = 285), which was defined as “mea-
sures designed to provide palliation of symptoms and 
improve quality of life as much as possible”33. Ap-
proximately 37% of patients enrolled in the study had 
received adjuvant therapy. The number of previous 
regimens, including adjuvant, was roughly 17% for 
one to two lines, 38% for three lines and 45% for four 
or more lines of therapy.  Compared with BSC alone, 
cetuximab significantly improved OS (hazard ratio 
[HR] 0.77; 95% CI 0.64–0.92; p = 0.005) and PFS 
(HR 0.68; 95% CI 0.57–0.80; p < 0.001). Median OS 
was 6.1 months in the group treated with cetuximab 
compared with 4.6 months in those receiving BSC 
alone. Twenty-three patients (8.0%) in the cetuximab 
group had partial responses compared with none in 
those assigned to BSC alone (p < 0.001); an additional 
31.4% of patients treated with cetuximab and 10.9% 
of patients assigned to BSC alone had stable disease 
(p < 0.001). 
Cetuximab was also shown to preserve quality 
of life to a greater extent than BSC. Compared with 
those who received BSC alone, patients treated with 
cetuximab experienced less deterioration in physical 
function at eight weeks (mean change score, –3.9 vs. 
–8.6; p < 0.05) and 16 weeks (mean change score, 
–5.9 vs. –12.5; p = 0.03), and less deterioration in 
global health status at eight weeks (mean change 
score, –0.5 vs. –7.1; p = 0.008) and 16 weeks (mean 
change score, –3.6 vs. –15.2; p < 0.001)33.
Because cetuximab targets the EGFR, most 
clinical trials of cetuximab in the treatment of mCRC 
include patients with EGFR-positive tumors, as deter-
mined by immunohistochemistry. However, the inten-
sity of EGFR immunostaining has not been shown to 
be related to the activity of cetuximab, and objective 
responses have been reported in patients with EGFR-
negative tumors35. An ongoing phase II, multicentre 
study is evaluating the efficacy of cetuximab in the 
absence of detectable EGFR expression34. Patients 
with refractory, EGFR-undetectable mCRC who 
had undergone at least one standard chemotherapy S5
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regimen containing fluoropyrimidine were given 
cetuximab in the standard dosage regimen and evalu-
ated for tumor response every six weeks. Preliminary 
results presented at the 2008 Annual Meeting of the 
American Society of Clinical Oncology (ASCO) 
revealed partial responses in six of the 85 patients 
who were evaluable for response (ORR 7%; 95% CI 
3%–15%)34. These preliminary results suggest that 
cetuximab monotherapy is comparably active in both 
EGFR-detectable and EGFR-undetectable disease, 
confirming the unreliability of EGFR immunohis-
tochemistry as an indicator of cetuximab activity.
3.1.2.  Cetuximab combination therapies
Cetuximab has also been evaluated in the first- and 
second-line treatment of mCRC in combination with 
cytotoxic chemotherapies. 
A phase I/II study evaluated the safety and ef-
ficacy of cetuximab in combination with FOLFIRI 
(irinotecan, leucovorin, fluorouracil) in 52 patients 
with previously untreated, unresectable mCRC36. The 
combination of cetuximab and FOLFIRI was active 
and well tolerated, with an overall response rate of 
48%, a median PFS of 8.6 months, and an OS of 22.4 
months. For those with initially unresectable metasta-
ses, treatment with cetuximab and FOLFIRI allowed 
27% to undergo resection, resulting in the elimination 
of residual tumor in 71% of these patients. Because of 
these resections, an accurate estimation of PFS was 
not possible, but these promising results prompted 
the design of the phase III CRYSTAL (Cetuximab 
Combined With Irinotecan in First-Line Therapy for 
Metastatic Colorectal Cancer) trial, which examined 
the efficacy of FOLFIRI in combination with cetux-
imab for the first-line treatment of mCRC37. The 
CRYSTAL trial randomly assigned 1198 patients 
with EGFR-positive mCRC to receive cetuximab 
plus FOLFIRI (n = 599) or FOLFIRI alone (n = 599). 
Following an updated analysis of the data in the ITT 
population, OS was found to be significantly longer 
in patients receiving cetuximab plus FOLFIRI com-
pared with FOLFIRI alone (median OS, 19.9 months 
vs. 18.6 months, HR 0.878, 95% CI 0.774-0.995, p = 
0.042). Among patients with wild-type KRAS tumors, 
OS (HR=0.796, 95% CI 0.670-0.946, p = 0.0094) and 
PFS (HR=0.696, 95% CI 0.558-0.867, p = 0.0012) 
were significantly greater with the addition of cetux-
imab to FOLFIRI than with FOLFIRI alone38.
The OPUS trial compared the response rates of 
FOLFOX-4 (leucovorin, fluorouracil, oxaliplatin) 
plus cetuximab with those of FOLFOX-4 alone for 
the first-line treatment of EGFR-positive mCRC39. 
Patients were randomly assigned in a 1:1 ratio to 
treatment with standard-dosage cetuximab plus 
FOLFOX-4 or to FOLFOX-4 only.  Among patients 
with wild-type KRAS tumors, PFS was significantly 
longer (8.3 months vs. 7.2 months, HR 0.567; 95% 
CI 0.375-0.856; p = 0.0064) and OR was significantly 
higher (57% vs. 34%, odds ratio 2.5512, 95% CI 
1.3799-4.7169; p = 0.0027) with the combination 
of cetuximab plus FOLFOX4 than with FOLFOX4 
alone40. The addition of cetuximab to FOLFOX4 was 
associated with a four-month improvement in OS 
(18.5 to 22.8 months) on KRAS wild-type patients; 
this difference was not statistically significant, likely 
because of the small number of patients available for 
analysis. However, in a recent meta-analysis of the 
OPUS and CRYSTAL trials, OS was significantly 
longer in patients with wild-type KRAS tumors treated 
with cetuximab plus chemotherapy than in those 
receiving chemotherapy alone (HR 0.81; 95% CI 
0.69–0.94; p = 0.006)41. The addition of cetuximab 
to chemotherapy was also found to reduce the risk 
of disease progression by 34% (HR 0.66; 95% CI 
0.55–0.80; p < 0.0001) and increase the likelihood 
of response by more than twofold (OR 2.16; 95% CI 
1.64–2.86; p < 0.0001) compared with chemotherapy 
alone in patients with wild-type KRAS tumors.
The EPIC (Erbitux Plus Irinotecan for Meta-
static Colorectal Cancer) study investigated whether 
adding cetuximab to irinotecan following failure of 
prior treatment with fluoropyrimidine and oxaliplatin 
would prolong survival in irinotecan-naive patients 
with EGFR-expressing mCRC42. This open-label, 
phase III study randomly assigned 1298 patients with 
EGFR-expressing mCRC who had experienced first-
line treatment failure with fluoropyrimidine and ox-
aliplatin to treatment with cetuximab plus irinotecan 
or irinotecan alone. The combination of cetuximab 
and irinotecan was associated with a 31% reduction 
in the risk of progression compared with irinotecan 
alone (p ≤ 0.0001, HR 0.692, 95% CI 0.617–0.776) 
and resulted in significantly better scores in the QOL 
analysis of global health status (p = 0.047). The 
response rate was also greater with cetuximab and 
irinotecan (16.4%, 95% CI 13.6–19.4) than with iri-
notecan alone (4.2%, 95% CI 2.8–6.0) (p < 0.0001). 
Complete responses were observed in nine patients 
receiving the combination versus one patient receiv-
ing irinotecan alone. The primary endpoint of OS 
was comparable between the two treatment groups, 
which was potentially confounded by the fact that 
46.9% of patients in the irinotecan arm went on to 
receive cetuximab.
The open-label, randomized BOND trial20 com-
pared the efficacy of cetuximab in combination with 
irinotecan with that of cetuximab alone in mCRC 
that was refractory to treatment with irinotecan. 
The BOND trial enrolled 329 patients with EGFR-
expressing mCRC whose disease had progressed 
despite treatment with an irinotecan-based regimen. 
Patients from 56 centers in 11 European countries 
were randomly assigned to receive either cetuximab 
and irinotecan (n = 218) or cetuximab monotherapy 
(n = 111 patients). In the event of disease progression, 
patients on cetuximab monotherapy were permitted 
to receive additional treatment with irinotecan. In 
this study, nearly 80% of the patients who underwent S6
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randomization had received two or more previous 
regimens. The overall response rates were 22.9% 
(95% CI 17.5–29.1%) in the combination therapy 
group and 10.8% (95% CI, 5.7–18.1%) in the mono-
therapy group (p = 0.007), with median durations of 
response of 5.7 months and 4.2 months, respectively. 
Disease control (complete response plus partial re-
sponse plus stable disease) was achieved in 55.5% 
and 32.4% of patients receiving combination treatment 
and cetuximab monotherapy, respectively (p < 0.001). 
Among those who had progressed during or within 
one month after irinotecan therapy, the response rates 
were 25.2% (95% CI, 18.1–33.4%) and 14.1% (95% 
CI, 7.0 –24.4%) in the combination therapy and 
monotherapy groups, respectively (p = 0.07). Of note, 
treatment with cetuximab was found to be as effective 
in patients who had previously received oxaliplatin in 
addition to irinotecan before entering the study, with 
response rates of 22.2% and 8.5% in the combination 
therapy and monotherapy groups, respectively (p = 
0.01). In the intention-to-treat analysis, the median 
time to progression of disease was 4.1 months in the 
combination-therapy group and 1.5 months in the 
monotherapy group (HR 0.54, 95% CI 0.42–0.71), 
indicating a 46% reduction in the risk of progression 
with combination therapy compared with mono-
therapy (p < 0.001) (Fig. 1). OS was not significantly 
different between the two groups (Fig. 2). 
The effectiveness of irinotecan in combination 
with cetuximab in patients with irinotecan-refractory 
mCRC suggests that cetuximab may have the abil-
ity to circumvent irinotecan resistance. It has been 
postulated that cells acquire irinotecan resistance 
through several mechanisms43, and cetuximab may 
overcome this resistance by inhibiting EGFR, thereby 
preventing drug efflux43-48, restoring apoptosis49 or 
impairing DNA-repair activity50,51.
The COIN trial evaluated whether the addition 
of cetuximab to continuous oxaliplatin-based che-
motherapy improves OS in the first-line treatment 
of mCRC. The 1630 patients in the study received 
one of two oxaliplatin-based regimens chosen by 
their physicians – either 5-fluorouracil (5FU) or 
capecitabine. An unexpected result of COIN was 
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Fi g u r e  1  Time to disease progression in patients treated with cetuximab alone or cetuximab plus irinotecan in the BOND trial20
Fi g u r e  2  Overall survival in patients treated with cetuximab alone or cetuximab plus irinotecan in the BOND trial20S7
Cu r r e n t On C O l O g y —VO l u m e  17, nu m b e r 1, Su p p l e m e n t 1
the lack of benefit in OS or PFS with the addition of 
cetuximab in patients with wild-type KRAS tumors; 
however, there was a significant increase in best 
overall response (p = 0.04). The chemotherapy used 
by over two-thirds of patients in COIN was XELOX, 
which includes two cytotoxic agents – capecitabine 
(Xeloda) and oxaliplatin. The other chemotherapy 
used in COIN was FOLFOX, consisting of bolus and 
infusional 5FU, folinic acid and oxaliplatin. While 
analyses of the capecitabine arm are not yet complete, 
results have shown higher rates of non-hematological 
toxicity leading to greater dose reductions in 47% 
of patients – from 1000 mg/m2 to 850 mg/m2, a po-
tentially suboptimal therapeutic dose in mCRC. As 
well, 9% of patients in COIN older than 75 years, and 
8% had ECOG 2 performance status. A trend toward 
improvement in PFS for the cetuximab arm was seen 
only in the FOLFOX group. This may suggest that 
the compounded toxicities seen in combination with 
XELOX overcame the potential benefits in terms 
of prolongation of disease control (dose reductions 
and delay). Further analyses are needed to examine 
issues of efficacy and toxicity related to the combi-
nation of cetuximab and capecitabine, and to further 
understand the impact of population characteristics 
on the overall results52.
Cetuximab has also been investigated in combi-
nation with the MoAb bevacizumab in the first-line 
treatment of mCRC, with conflicting results. The 
BOND2 study showed that the combination of bevaci-
zumab and cetuximab, with or without irinotecan, im-
proved response rates and time to tumor progression 
in heavily pretreated, irinotecan-refractory mCRC53. 
The CAIRO2 trial randomly assigned 755 patients 
with previously untreated mCRC to capecitabine, 
oxaliplatin, and bevacizumab (n = 378) or to the same 
regimen plus the addition of weekly cetuximab (n = 
377)54. The addition of cetuximab to capecitabine, 
oxaliplatin, and bevacizumab resulted in significantly 
shorter PFS (9.4 months vs. 10.7 months, p = 0.01) 
and inferior quality of life scores. 
4.  PAnITuMuMAB
4.1  Panitumumab monotherapy
Panitumumab has demonstrated clinical activity as 
a single agent in patients with mCRC who have pro-
gressed on chemotherapy. The anti-tumor activity of 
panitumumab was established in a multicentre, phase 
II study of mCRC patients with EGFR tumor expres-
sion levels of 10% or higher who had progressed 
during or following treatment with fluoropyrimidine, 
irinotecan, and oxaliplatin treatment15. Patients were 
treated with panitumumab 6 mg/kg every two weeks 
until disease progression. Of the 39 patients included 
in the efficacy data set, three (8%) had a partial re-
sponse, eight (21%) had stable disease, and 19 (49%) 
had disease progression at 16 weeks.
In a phase II open label, multicentre study, 148 
patients with EGFR-positive mCRC underwent 
weekly treatment with panitumumab 2.5 mg/kg, 
resulting in a response rate of 9% and PFS of 14 
weeks55. The response rate was not affected by the 
number of prior treatment regimens nor by the level 
of EGFR staining. These results are supported by 
data from a phase II multicentre, single-arm study 
showing a response to panitumumab in patients with 
low or negative EGFR tumor cell expression56. Pa-
tients with chemorefractory mCRC and low (< 1%) 
or negative (1% to 9%) EGFR tumor cell expression 
were treated with panitumumab 6 mg/kg every two 
weeks until disease progression or intolerability. 
Overall responses were similar between the low-
EGFR and negative-EGFR groups, as were median 
time to response, duration of response, and incidence 
of adverse events56.
The effect of panitumumab monotherapy has 
also been compared with BSC in the treatment of 
EGFR-positive mCRC57. Patients were randomly 
assigned to panitumumab 6 mg/kg given every two 
weeks along with BSC (n = 231) or BSC alone (n = 
232). Approximately 37% of patients had received 
prior adjuvant therapy. One hundred percent and ap-
proximately 37% of patients had received two and 
three prior lines of therapy, respectively. Six percent 
of patients in each arm received more than three 
prior lines of therapy; these patients were enrolled 
before a protocol amendment that limited entry cri-
teria to two to three prior lines of therapy. PFS was 
significantly improved by panitumumab, with a mean 
PFS of 13.8 (SE 0.8) weeks, compared with 8.5 (SE 
0.5) weeks for BSC (HR 0.54; 95% CI 0.44–0.66, 
p < 0.0001). Objective response rates were also im-
proved by panitumumab, with response rates of 10% 
for panitumumab and 0% for BSC after a 12-month 
minimum follow-up (p < 0.0001). An additional 62 
(27%) patients in the panitumumab group and 23 
(10%) patients in the BSC group had a best response 
of stable disease, with similar results seen in the group 
of patients who were permitted to cross over to pa-
nitumumab following progression on BSC alone. In 
an exploratory analysis, in which patients with stable 
disease were removed from the panitumumab group, 
approximately 80% of the overall treatment effect on 
PFS was attributed to nonresponders, suggesting that 
stable disease is associated with a significant clini-
cal benefit in this patient population. An OS benefit 
was not observed, likely confounded by the similar 
activity of panitumumab after 76% of patients in the 
BSC group entered into the crossover study. In the 
extension phase of the study58, 176 patients whose 
disease had progressed while receiving BSC in the 
phase III study received one or more dose of panitu-
mumab. Objective responses were observed in 11% 
of patients, and an additional 33% of patients had a 
best response of stable disease, with a disease control 
rate of 44%. 
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4.2  Panitumumab combination therapies
Studies evaluating panitumumab for the first- and 
second-line treatment of mCRC in combination with 
cytotoxic chemotherapies are limited. The phase II 
multicentre, single-arm PACCE (Panitumumab Ad-
vanced Colorectal Cancer Evaluation) study evalu-
ated the efficacy and safety of adding panitumumab 
to combination chemotherapy with bevacizumab for 
the first-line treatment of mCRC59. The PACCE trial 
was stopped early when a planned interim analysis 
revealed that both PFS and OS were better in the 
standard chemotherapy arm versus the panitumumab 
plus chemotherapy arm. In contrast to the CAIRO2 
trial, which evaluated the combination of cetuximab 
and bevacizumab in the treatment of mCRC, in the 
PACCE trial, worse outcomes were seen in the pani-
tumumab group.  
The recently completed PRIME study was the first 
global, phase III trial to investigate the combination 
of an anti-EGFR monoclonal antibody with FOLFOX 
as first-line treatment for patients with mCRC60. In 
PRIME, 1183 patients were randomly assigned in 1:1 
ratio to biweekly treatment with either panitumumab 
6.0 mg/kg plus FOLFOX4 or FOLFOX4 alone. When 
administered in combination with FOLFOX, panitu-
mumab significantly prolonged PFS compared with 
FOLFOX alone (9.6 months vs. 8.0 months; HR = 
0.80; 95% CI 0.66–0.97; p = 0.0234) in the first-line 
treatment of patients with KRAS wild-type mCRC. 
Median OS was prolonged by 4.2 months with the 
addition of panitumumab to FOLFOX compared with 
FOLFOX alone (23.9 months vs. 19.7). However, 
this difference did not reach statistical significance 
(HR=0.83, p = 0.072) (Amgen, unpublished data).
The phase III 181 trial evaluated the efficacy 
of adding panitumumab to FOLFIRI as second-line 
therapy for mCRC61.  A total of 1186 patients were 
randomly assigned to treatment with biweekly panitu-
mumab 6.0 mg/kg plus FOLFIRI (Arm 1) (n = 591) or 
FOLFIRI alone (Arm 2) (n = 595). For patients with 
wild-type KRAS, the combination of panitumumab 
and FOLFIRI improved median PFS (5.9 months vs. 
3.9 months; HR 0.73; 95% CI 0.593–0.903; p = 0.004) 
and response rate (by blinded central review) (35% 
vs. 10%) compared with FOLFIRI alone. Median OS 
was not significantly different among the two groups, 
and there was no difference in PFS, OS, or response 
rate among patients with mutant KRAS. 
A randomized, phase III study has also evaluated 
the efficacy of adding panitumumab to FOLFIRI in 
the second-line treatment of mCRC62. A total of 1186 
patients with metastatic adenocarcinoma of the colon 
or rectum, documented disease progression of six 
months or less after one prior therapy with fluoropy-
rimidine for mCRC, and an ECOG score of 0–2 were 
randomly assigned to treatment with panitumumab 
plus FOLFIRI or FOLFIRI alone. Among patients 
with wild-type KRAS tumors, PFS was significantly 
increased from 3.9 months to 5.9 months (HR 0.73; 
95% CI 0.59-0.90; p = 0.004), and there was a non-
significant increase in OS from 12.5 months to 14.5 
months (HR 0.85; 95% CI 0.70-1.04; p = 0.12) with 
the addition of panitumumab to FOLFIRI compared 
with FOLFIRI alone.
5.  AlTERnATIvE DOSInG REGIMEnS fOR 
CETuxIMAB AnD PAnITuMuMAB
Cetuximab is currently approved in a weekly dosing 
regimen25. However, as many chemotherapy regimens 
are administered every second week, it would be 
convenient and cost-effective if cetuximab adminis-
tration could be coordinated with the chemotherapy 
schedule63. Preliminary results from a two-part, phase 
I study of patients with EGFR-expressing mCRC who 
had not received previous chemotherapy demonstrated 
that the pharmacokinetics of cetuximab were com-
parable between a weekly 250 mg/m2 regimen and 
a regimen of cetuximab 500 mg/m2 given every two 
weeks63. These data prompted a group in Denmark to 
begin treating a group of patients with nonresectable 
mCRC who had failed to respond to 5-fluorouracil, 
irinotecan, and oxaliplatin, according to a biweekly 
treatment schedule of cetuximab and irinotecan64. 
Among the initial 74 patients treated according to 
this dosing schedule for one year, 1% and 24% of 
patients experienced complete and partial responses, 
respectively, compared with 0% and 19% in a control 
group receiving the standard weekly dosing regimen. 
Median PFS was 5.4 months with both the biweekly 
and weekly regimens, and OS was 8.9 months and 
10.4 months in the biweekly and weekly groups, re-
spectively (Table 1). These efficacy data are similar to 
the efficacy of the weekly regimen described in other 
studies20,63,65. Toxicity data were also comparable with 
those from studies where cetuximab is administered on 
a weekly basis20,66. Salvage therapy with simplified bi-
weekly cetuximab plus irinotecan may therefore offer 
a convenient, effective and well-tolerated regimen in 
patients with mCRC who are resistant to 5-fluorouracil, 
irinotecan, and oxaliplatin20,66. An ongoing phase II 
study is underway to confirm these findings.
Similar results were seen in a phase II, institution-
al exploratory trial of irinotecan and cetuximab given 
in a biweekly dosing regimen to patients with mCRC 
who had disease progression following at least one 
previous line of chemotherapy67. Forty patients were 
treated with irinotecan 180 mg/m2 and cetuximab 500 
mg/m2 every two weeks until unacceptable toxicity 
or progressive disease. With two complete responses 
and seven partial responses, the overall response rate 
was 22.5%. The disease control rate was 60%, time 
to progression was 3.4 months, and OS was eight 
months. Toxicities were favorable compared with 
weekly cetuximab combination schedules. 
These preliminary data suggest that biweekly 
dosing of cetuximab may offer a convenient 
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strategy for the treatment of mCRC, without com-
promising efficacy.
Extended dosing strategies have also been explored 
with panitumumab. Panitumumab is currently approved 
for biweekly administration, and its safety and effi-
cacy for administration every three weeks have been 
explored68,69. A phase I study of 96 patients with various 
tumor types randomly assigned patients to treatment 
with one of three dosing schedules of panitumumab 
– 2.5 mg/kg weekly, 6.0 mg/kg every two weeks, and 
9.0 mg/kg every three weeks. The minimal serum pani-
tumumab concentrations were similar among the three 
dosing strategies, with steady-state reached after six 
weeks for all schedules. These data suggest that pani-
tumumab may be flexibly dosed from weekly to every 
three weeks69. However, another study showed higher 
rates of several grade 3 adverse events (erythema, pru-
ritus, acneiform dermatitis, fatigue, hypomagnesemia) 
with the every three weeks regimen69. 
6.  MARKERS Of RESPOnSE TO AnTI-EGfR 
MOAB ThERAPY: PATIEnT SElECTIOn
Despite the demonstrated efficacy of the anti-EGFR 
therapies in the treatment of mCRC, response rates 
in unselected patient populations have remained 
low15,20,31-34,36,37,42,55-58, prompting the search for 
markers to identify patients who are most likely to 
benefit from anti-EGFR therapy. As described above, 
EGFR testing by immunohistochemistry has not 
demonstrated value in predicting which patients will 
respond to cetuximab or panitumumab20,31, and ob-
jective responses have been observed in patients who 
do not express EGFR35,55. Several biologic markers 
involved in EGFR intracellular signaling pathways 
have been investigated as potential predictors of re-
sponse to the anti-EGFR MoAbs.
6.1  KRAS mutational status
6.1.1  Cetuximab
Recent reports have shown that the presence of 
mutations on the KRAS gene is a strong predictor of 
nonresponsiveness to cetuximab70-74. In order to iden-
tify gene expressions that correlate with best clinical 
response to cetuximab, 110 patients with mCRC 
were enrolled in a monotherapy trial and underwent 
transcriptional profiling on RNA from mandatory pre-
treatment metastatic biopsies71. Significantly higher 
rates of disease control were seen in patients whose 
tumors lacked the KRAS mutations than in those with 
KRAS mutations (p = 0.0003). 
In a follow-up to the phase III CO.17 trial, cor-
relative analysis was used to determine whether 
the mutation status of the KRAS gene modified the 
effect of cetuximab on OS and PFS in this patient 
population73. Among patients with wild-type KRAS, 
median OS was significantly greater among patients 
treated with cetuximab (9.5 months) than among those 
treated with BSC (4.8 months), while patients with 
KRAS mutations did not experience an OS benefit 
from cetuximab.
Several recent studies have shown that KRAS 
mutational status also plays a key role in response 
and survival in patients with irinotecan-resistant 
mCRC who are treated with cetuximab and irinote-
can. Among 281 patients from seven series, all 77 
responses – including three complete responses and 
74 partial responses – were in patients with wild-type 
KRAS tumors74. 
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Ta b l e  I.  Efficacy of treatment with weekly cetuximab and irinotecan (CetIri) or biweekly CetIri in two consecutive periods64
Characteristic Weekly CetIri 250 mg/m2 Biweekly CetIri 500 mg/m2
Number  65 74
Time from nonresectable disease to ‘indication for 
cetuximab’, months (range)
20 (5–58) 16 (3–60)
Median ‘delay’ time, time from date of indication to 
the first infusion of CetIri, weeks (range)
6 (0–88) 6 (0–36)
Median number of weeks with cetuximab (range) 16 (1–51) 17 (2–52)  
(8 biweekly courses)
Response rate
Complete response (CR) 0 1 (1%)
Partial response (PR) 12 (19%) 18 (24%)
Stable disease (SD) 31 (47%) 38 (52%)
Disease control (CR + PR + NC) 43 (66%) 57 (77%)
Progression (PD) 15 (23%) 13 (18%)
Not evaluable 7 (11%) 4 (5%)
PFS, months (95% CI) 5.4 (4.6–6.1) 5.4 (4.7–6.5)
OS, months (95% CI) 10.4 (7.2–13.1) 8.9 (7.0–10.5)
NC = No change; PFS = Progression-free survival; OS = Overall survivalS10
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In the CRYSTAL trial, which showed a reduction 
in the risk of progression of mCRC with the addition 
of cetuximab to FOLFIRI, retrospective subgroup 
analysis revealed that the benefit of cetuximab on tu-
mor response was limited to patients with KRAS wild-
type tumors37.  DNA was extracted from 540 available 
archived tumor samples from the CRYSTAL trial to 
determine KRAS mutation status75. Among patients 
with wild-type KRAS, the addition of cetuximab to 
FOLFIRI significantly increased the overall response 
rate (57.3 % vs. 39.7%, OR 2.1, 95% CI 1.5-2.9,  p < 
0.0001) and PFS (9.9 months vs. 8.4 months, HR 0.7, 
95% CI 0.56-0.87, p = 0.0012). Median OS was also 
extended among patients with wild-type KRAS – from 
20.0 months to 23.5 months (HR 0.796, 95% CI 0.67-
0.95, p = 0.0094)41. Patients with KRAS mutations did 
not benefit from the addition of cetuximab.
When analyses of patients in the OPUS trial were 
repeated in order to evaluate the influence of KRAS 
mutation status on response to treatment76, only 
those with wild-type KRAS tumors benefited from 
the addition of cetuximab to FOLFOX. The addition 
of cetuximab to FOLFOX in the first-line setting 
improved the response rate (57 % vs. 34%, 95% 
CI 1.34-4.72, p = 0.0027), PFS (8.3 months vs. 7.2 
months, HR 0.57, 95% CI 0.38-0.89, p = 0.0064) and 
OS (22.8 months vs. 18.5 months, HR 0.86 95% CI 
0.60-1.22, p = 0.3854) compared with FOLFOX alone 
among mCRC patients with wild-type KRAS tumors. 
Patients with KRAS mutations did not benefit from 
the addition of cetuximab to FOLFOX and, in fact, 
experienced significantly reduced PFS (5.5 months vs. 
8.6 months, HR 1.72, p = 0.02) and OS (13.4 months 
vs. 17.5 months, HR 1.29, p = 0.2) compared with 
those who were treated with FOLFOX alone41.
In the CAIRO2 trial, which showed a negative 
effect of cetuximab on PFS when added to a treat-
ment regimen of capecitabine, oxaliplatin, and beva-
cizumab for previously untreated mCRC, among the 
subgroup of patients with wild-type KRAS tumors, 
PFS was not significantly different between the two 
groups, and there was a trend toward improved risk 
reduction with the addition of cetuximab. OS was not 
affected by the addition of cetuximab54.
Cetuximab has been suggested to exert antitumor 
effects through ADCC, which occurs as a result of 
interaction of the Fc portion of the antibody with Fc 
receptors (FcgammaRs) expressed by immune cells. 
Bibeau et al. explored the association of FcgammaR 
polymorphisms and KRAS mutation with clinical out-
comes of patients with irinotecan-refractory mCRC 
treated with cetuximab plus irinotecan77. Tumor and 
normal tissues from 69 patients were screened for 
KRAS mutations and genotyped for FcgammaRIIa and 
FcgammaRIIIa polymorphisms. Patients with KRAS 
mutations had lower response rates (4% vs. 27%, p = 
0.021) and shorter PFS (3.0 vs. 5.3 months, p = 0.021) 
than those with wild-type KRAS tumors. FcgammaRI-
Ia-131H/H and FcgammaIIIa-158V/V genotypes were 
associated with longer PFS than 131R and 158F geno-
types (5.5 vs. 3.0 months, p = 0.005) – regardless of 
KRAS status. The clinical relevance of the FcgammaR 
polymorphisms in this study, regardless of KRAS status, 
suggests that ADCC may be an important contributor 
in the mechanism of action of cetuximab. 
6.1.2  Panitumumab
Patients with mCRC with KRAS mutations are less 
likely to respond to therapy with panitumumab. In 
the phase III, randomized trial by Van Cutsem et 
al. comparing panitumumab and BSC in chemo-
therapy-refractory mCRC57, biomarker analyses 
were conducted to determine whether the effect of 
panitumumab monotherapy on PFS differed among 
patients whose tumors contained mutant KRAS and 
those whose tumors contained wild-type KRAS78. Of 
the 463 patients enrolled in the original study, 427 
were included in the KRAS analysis. KRAS mutations 
were detected in 43% of patients in the panitumumab 
group and 40% of patients in the group receiving 
BSC. Patients with wild-type KRAS experienced a 
significantly greater relative improvement in PFS with 
panitumumab treatment versus BSC (HR 0.45; 95% 
CI 0.34 to 0.59). No benefit of panitumumab was seen 
among patients with mutant KRAS tumors (HR 0.99; 
95% CI 0.73 to 1.36).  Because of the crossover design 
of the study, whereby 77% of patients with mutant 
KRAS and 76% of patients with wild-type KRAS in 
the BSC group received panitumumab, an effect on 
OS could not be determined.
Freeman et al. determined the KRAS status of 
patients from three phase II studies of panitumumab 
monotherapy in the treatment of mCRC79. Of the 62 
tumor samples available for genomic DNA sequenc-
ing, 38.7% had a KRAS mutation and 61.4% had wild-
type KRAS. Wild-type KRAS was significantly associ-
ated with response to panitumumab (p = 0.0028). 
The STEPP80 and PRECEPT81 studies are evalu-
ating second-line treatment with panitumumab plus 
irinotecan in patients with unresectable mCRC who 
failed first-line treatment with oxaliplatin-based 
chemotherapy including bevacizumab. Both stud-
ies assessed patients for KRAS tumor status. STEPP 
randomly assigned patients to treatment with either 
panitumumab plus FOLFIRI or to panitumumab plus 
irinotecan. In the single-arm PRECEPT trial, patients 
received panitumumab 6 mg/kg plus FOLFIRI every 
two weeks until disease progression. Interim analysis 
have showed improved efficacy among patients with 
wild-type KRAS.
The recently completed PRIME study was the first 
global, phase III trial to investigate the combination 
of an anti-EGFR monoclonal antibody with FOLFOX 
as first-line treatment for patients with mCRC60. In 
PRIME, 1183 patients were randomly assigned in 1:1 
ratio to biweekly treatment with either panitumumab 
6.0 mg/kg plus FOLFOX4 or FOLFOX4 alone, with 
a primary endpoint of PFS. Secondary endpoints 
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included OS, objective response rate, time to pro-
gression, duration of response, and safety. Patients 
were also stratified in each arm according to their 
KRAS mutational status to identify its applicability 
as a potential biomarker for panitumumab activity. 
When administered in combination with FOLFOX, 
panitumumab significantly prolonged progression-
free survival (PFS) compared with FOLFOX alone 
(9.6 months vs. 8.0 months; HR = 0.80; 95% CI 
0.66–0.97; p = 0.0234) in the first-line treatment of 
patients with KRAS wild-type mCRC82. 
6.2  Other genetic markers of response
6.2.1  BRAF mutations
As KRAS mutations account for only 30–40% of pa-
tients who do not respond to EGFR inhibitors70,83-86, 
additional genetic determinates of resistance to EGFR 
inhibitors in mCRC are needed. In the absence of 
KRAS mutations, resistance to anti-EGFR therapies is 
thought to be caused by alternations of other members 
of the RAS-RAF-MAPK pathway87. 
Using retrospective genetic analyses of 113 tumors 
from cetuximab- and panitumumab-treated mCRC 
patients, Di Nicolantonio et al. assessed whether BRAF 
mutations affect response to treatment with these 
anti-EGFR MoAbs87. KRAS mutations were present 
in 30% of patients and, as expected, were associated 
with resistance to anti-EGFR therapy (p = 0.011). 
BRAF mutations were detected in 14% of patients 
with wild-type KRAS tumors, and were associated 
with nonresponse to anti-EGFR therapy (p = 0.029). 
Patients with BRAF mutations also had significantly 
shorter PFS (p = 0.011) and OS (p < 0.0001) compared 
with patients with wild-type BRAF tumors.
Recently, Ruzzo et al. retrospectively assessed 
KRAS and BRAF mutational status in 117 irinotecan-
refractory EGFR-positive mCRC patients treated with 
cetuximab plus irinotecan88. Among the 66 patients 
with wild-type KRAS, nine had BRAF mutations and 
57 had wild-type BRAF tumors. Those with wild-type 
BRAF experienced significantly improved RR (0% 
vs. 33%, p = 0.04) and PFS (3.3 vs. 5.1 months, p = 
0.076; HR=0.54; 95% CI 0.18–1.09) compared with 
those with mutated BRAF. 
In a recent report of 276 chemorefractory mCRC 
patients treated with cetuximab (with or without 
irinotecan), those with a combined wild-type KRAS, 
BRAF and NRAS status experienced a significantly 
greater response, progression-free survival, and OS 
compared with patients with a mutation in one of 
these genes89. Mutations of KRAS, BRAF and NRAS 
were shown to be mutually exclusive and present in 
at least 47% of mCRC patients89. 
In a recent analysis of the CAIRO2 trial, which 
evaluated the efficacy of chemotherapy plus beva-
cizumab with or without the addition of cetuximab 
in patients, patients with BRAF mutated tumors 
were found to have decreased median PFS and OS 
compared with patients with wild-type tumors, irre-
spective of the treatment arm90. These results suggest 
that, in contrast to KRAS mutations, the association 
of BRAF with outcome is not restricted to patients 
treated with cetuximab.
6.2.2  Overexpression of epiregulin and amphiregulin
Overexpression of the EGFR ligands epiregulin and 
amphiregulin in primary tumors has been associated 
with favorable outcomes in mCRC patients treated 
with cetuximab71,91 – a finding that is limited to pa-
tients with wild-type KRAS tumors91,92. In the NCIC 
CTG CO.17 study, tumor samples were analyzed and 
the cohort was subdivided into those with low or high 
EREG. Results demonstrated that OS was better for 
cetuximab than BSC among patients with high EREG 
(HR 0.43; p < 0.0001) but not for low EREG patients 
(HR 0.77, p = 0.28)93. High EREG AND KRAS WT 
status (“Combimarker”) was present in 139 (36%). 
Within the Combimarker-positive group, the median 
PFS was 5.4 vs. 1.9 months (HR, 0.31; p < 0.0001), 
and median OS 9.8 vs. 5.1 months (HR, 0.43; p < 
0.001) in the cetuximab vs. BSC arms, respectively. In 
the rest (n = 246, 64%), cetuximab was not associated 
with improved PFS (HR, 0.82; p = 0.12) or OS (HR, 
0.90; p = 0.45)93.
It is likely that tumors overexpressing these mark-
ers are more dependant on EGFR activation and there-
fore more likely to respond to anti-EGFR MoAbs94. 
6.2.3  EGFR gene copy number
EGFR gene copy number has also shown to be corre-
lated with response to anti-EGFR MoAb therapy95,96. 
In a report of 31 patients with mCRC treated with 
cetuximab or panitumumab, those who responded to 
anti-EGFR therapy had a median EGFR gene copy 
number of 6.8 per cell compared with a median of 
1.93 in nonresponders83. 
In the phase III trial comparing panitumumab 
plus BSC and BSC alone, a subset of patients had 
tumor samples adequate to determine gene copy 
number by FISH. Among the 58 patients treated with 
panitumumab for mCRC, 2.47 was identified as the 
cutoff gene copy number for response, with an over-
all accuracy of 75.9% (95% CI, 62.8% to 86.1%)95. 
No patient with an EGFR gene copy number below 
2.47 had a tumor response, while six of 20 patients 
with an EGFR gene copy number above 2.47 had an 
objective response (p = 0.0009). 
In a retrospective analysis of 85 chemorefractory 
mCRC patients, a gene copy number of 2.92 was found 
to be predictive of response to treatment with cetux-
imab-based therapy96. A response rate of 32.6% was 
observed among those with a gene copy number higher 
than 2.92, compared with a response rate of 2.4% in 
those with a gene copy number less than 2.92. 
The combination of gene copy number and 
KRAS status may be more predictive of response to 
anti-EGFR therapy than KRAS alone97. In a study 
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of 87 patients with mCRC treated with cetuximab, 
either alone or in combination with irinotecan, pa-
tients with wild-type KRAS tumors and a gene copy 
number higher than 2.83 were less likely to progress 
than those with a lower gene copy number97. An un-
expected result was that gene copy numbers higher 
than 2.83 were associated with a higher likelihood 
of progression among patients with mutant KRAS 
tumors. These findings require validation in a large 
prospective trial.
6.2.4  PTEN
PTEN is a key tumor suppressor that inactivates 
PI3K, a downstream effector of the EGFR cascade. 
Mutations resulting in PTEN loss lead to uncontrolled 
activation of PI3K/AKT signaling pathway, which 
may result in resistance to EGFR-blockade. The role 
of PTEN immunoreactivity (IHC) loss and of pAKT 
IHC in predicting the activity of treatment with a 
combination of cetuximab plus irinotecan was inves-
tigated in the primary tumors and metastases of 102 
EGFR-positive mCRC patients who had undergone 
previous treatment with irinotecan98. Loss of PTEN 
IHC in metastases, but not primary tumors, was pre-
dictive of response to treatment and was associated 
with greater PFS. pAKT IHC was not associated with 
response in primary tumors nor in metastases.
6.2.5  EGF/EGFR polymorphisms
EGF and EGFR polymorphisms are also potential 
markers of response to anti-EGFR therapy. Among 
110 patients treated with cetuximab and irinotecan 
following disease progression with first-line FOL-
FOX and a second-line irinotecan-based regimen, 
patients with a short-repeat variant of the highly 
polymorphic CA dinucleotide repeat in intron-1 of the 
EGFR gene were more responsive to treatment and 
had an increased rate of skin rash than patients with a 
long-repeat variant of CA99. In experimental models, 
decreasing the number of CA pairs has been shown 
to enhance EGFR transcription100; this may render 
tumors more dependent on the EGF pathway and, 
therefore, more responsive to EGFR inhibition.
Garm-Spindler et al. investigated the method-
ological aspects of KRAS testing, and the predictive 
and prognostic value of KRAS status combined with 
three EGFR-related gene polymorphisms in mCRC 
patients treated with third-line cetuximab and irino-
tecan101. Response was limited to patients with wild-
type KRAS tumors, translating to a significantly higher 
PFS. The EGF61A>G polymorphism was found to 
be significantly associated with clinical outcome in 
patients with wild-type KRAS mutations. Patients 
with homozygous EGF61 tumors had a significantly 
lower rate of progression (19% vs. 60%, p = 0.006) 
and a significant increase in OS (17.1 vs. 5.9 months, 
p = 0.002) in comparison with those with EGF61A/G 
tumors. Combined biomarker analysis to determine 
KRAS and EGF61 status may therefore offer an 
additional approach to the selection of patients for 
third-line treatment involving anti-EGFR therapies.
6.3  Papulopustular rash
EGFR blockade by cetuximab or panitumumab alters 
the mediation of epidermal basal keratinocytes by 
EGFR, resulting in the characteristic papulopustular 
rash. In most clinical trials, the incidence and severity 
of the rash has been well correlated with a clinical 
benefit of anti-EGFR therapy33,55,57,58.
In the BOND trial, clinical response rates were 
higher among patients who experienced skin reactions 
in response to cetuximab treatment (25.8% vs. 6.3% 
in the combination therapy group [p = 0.005] and 
13.0% vs. 0% in the monotherapy group)20.
Among 346 patients with EGFR-expressing 
mCRC refractory to irinotecan, oxaliplatin, and 
fluoropyrimidines, OS among patients treated with 
cetuximab correlated strongly with the presence and 
severity of rash32. Grade 1 and grade 2–3 rash were 
associated with median survival times of 4.9 months 
(95% CI 3.6–6.6 months) and 9.4 months (95% CI 
8.1–11.0), respectively (Fig. 3), compared with 1.7 
months (95% CI, 1.2 to 2.3) for patients without 
rash. Response was also strongly correlated with the 
presence and severity of rash. Of the 311 patients 
who developed rash, 13% (95% CI 9.3–17.1%) ex-
perienced a partial response. Partial responses were 
observed in 7%, 17%, and 20% of patients with grade 
1, 2, or 3 rashes, respectively, and in none of the 35 
patients without rash. 
The presence and severity of rash has also been 
correlated with clinical efficacy in trials of panitu-
mumab. In the phase III trial comparing panitumumab 
and BSC in the treatment of mCRC, PFS appeared 
to favor patients with grade 2–4 skin toxicity versus 
those with grade 1 skin toxicity (HR 0.62; 95% CI 
0.44–0.88)57. There was also a trend toward longer 
OS in patients with grade 2–4 skin toxicity compared 
with patients with grade 1 skin toxicity (HR 0.70, 
95% CI 0.47–1.05)58.
Data from the recent EVEREST trial (Evalua-
tion of Various Erbitux Regimens by Means of Skin 
and Tumor Biopsies), involving patients with no or 
limited skin reactions, suggest that individualized 
dose titration based on the occurrence and severity 
of rash might be used to improve treatment response 
to EGFR inhibitors102. However, as the rash only ap-
pears after treatment, its value as a predictive marker 
is somewhat limited94. 
7.  COnCluSIOnS
The anti-EGFR therapies cetuximab and panitu-
mumab have both demonstrated clinical efficacy in 
monotherapy in patients with mCRC, an advantage 
that has recently been found to be limited largely to 
those with wild-type KRAS tumors. The advantages S13
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of using these agents in monotherapy include reduced 
cost and toxicity. The addition of cetuximab to irino-
tecan results in superior PFS and RR compared with 
cetuximab monotherapy, and is the preferred regimen 
for patients with irinotecan-resistant mCRC. There is 
currently no evidence for a benefit of panitumumab 
in combination with irinotecan.
In the first-line setting, cetuximab has been 
shown to improve PFS and response rate in patients 
with wild-type KRAS tumors, in combination with 
FOLFOX and FOLFIRI chemotherapy. Cetuximab 
has also been shown to improve the potential for 
curative resections when added to chemotherapy 
(FOLFOX or FOLFIRI). Used alone in the third-
line setting, cetuximab has also been shown to 
improve OS and PFS in patients with wild-type 
KRAS tumors33,73.
Despite the efficacy of the anti-EGFR MoAbs 
in the treatment of mCRC, response rates remain 
suboptimal. In order to optimize treatment with these 
targeted therapies, it is important to select the patients 
who are most likely to benefit from treatment. Several 
biologic markers involved in EGFR intracellular sig-
naling pathways have been investigated as potential 
predictors of response to the anti-EGFR MoAbs. 
The most relevant of these markers is KRAS, and 
patients with KRAS mutations do not benefit from 
treatment with cetuximab or panitumumab. Other 
markers, such as BRAF, epiregulin and amphiregulin, 
EGFR gene copy number, PTEN, and EGF/EGFR 
polymorphisms, are currently under investigation 
and show promise but are considered experimental 
at this time94.
While cetuximab is currently administered 
according to a weekly dosing schedule, pharma-
cokinetic data indicate that it has a long terminal 
half-life, potentially allowing administration on a 
biweekly basis. A biweekly dosing schedule would 
allow greater treatment flexibility when combined 
with biweekly or longer chemotherapy regimens, as 
well as potential cost savings. Results from phase I 
studies show that a biweekly schedule of cetuximab 
is well tolerated, and exhibits similar pharmacokinet-
ics and pharmacodynamics to conventional weekly 
dosing, without compromising efficacy64,103. Pani-
tumumab, which is currently approved for biweekly 
administration, has been evaluated for administration 
every three weeks. Although pharmacokinetic data 
suggest that it may be flexibly dosed from weekly 
to every three weeks68, other data suggest higher 
rates of several grade 3 adverse events (erythema, 
pruritus, acneiform dermatitis, fatigue, hypomag-
nesemia) with this regimen69. Further evaluation 
of alternative dosing regimens for cetuximab and 
panitumumab is needed due to the small number of 
patients in these studies.
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